Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01609348 · ClinicalTrials.gov registry record · NA

Venlafaxine for Depression in Alzheimer's Disease (DIADs-3)

A NA study of Depression and Alzheimers Disease, sponsored by Johns Hopkins University.

Completed
Registry status
NA
Development phase
5
Enrollment target
2
Study locations

NCT01609348: Completed NA study of Depression and Alzheimers Disease, sponsored by Johns Hopkins University.

NCT01609348 is a NA study of Depression and Alzheimers Disease that has completed, run by Johns Hopkins University. The registered enrollment target is 5 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT01609348, a NA study of Depression and Alzheimers Disease, has completed, sponsored by Johns Hopkins University.

COMPLETED
Registry status
NA
Development phase
5 participants
Enrollment target
2
Study locations

Study Summary

This study will test the use of venlafaxine to treat the depression in Alzheimer's Disease. Venlafaxine works by increasing natural substances in the brain (serotonin and norepinephrine) that help maintain mental balance. Alzheimer's disease (AD) is the commonest neurodegenerative disease of aging and the cause of major financial and emotional burden to patients, families and caregivers, and society. Depression is a very common symptom of AD, affecting as many as 50% of patients over their illness. Depression in AD (Alzheimer's disease) contributes greatly to patient disability and caregiver distress. Neither psychosocial interventions nor psychotropic medications have proven effective to date for the treatment of depression in AD.Venlafaxine is approved by the U.S. Food and Drug Administration (FDA) for the treatment of major depression but it is not known whether or not it can help depression in Alzheimer's Disease.

Primary Outcome

Treatment will be considered efficacious if the proportion of worse categories (including 'minimal worsening', 'moderate worsening', or 'marked worsening') is lower under treatment than control on the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. Clinical Global Impression of Change: This is a 7-item score ranging from "markedly worse" to "markedly improved". It is assessed by the study clinician who interviews both participant and informant and makes an informed j

Conditions Studied

Depression Alzheimers Disease

Interventions

  • DRUG Placebo
  • DRUG Venlafaxine

Study Locations (2)

Maryland

  • Johns Hopkins at Bayview - Baltimore

Pennsylvania

  • Reading Hospital - West Reading

Trial Details

FieldValue
Enrollment Target 5 participants
Start Date 2012-04
Est. Completion 2017-01
Phase NA
Johns Hopkins University

1,448 total trials

What the finished NCT01609348 record still lists

NCT01609348 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 786-participant average among 679 other Depression trials with a reported enrollment target (99% lower).

The record links to 2 conditions, with Depression appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT01609348 reports a single indexed study location in Maryland, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT01609348 about?

NCT01609348 is a clinical study titled "Venlafaxine for Depression in Alzheimer's Disease (DIADs-3)". This study will test the use of venlafaxine to treat the depression in Alzheimer's Disease. Venlafaxine works by increasing natural substances in the brain (serotonin and norepinephrine) that help maintain mental balance. Alzheimer's disease (AD) is the commonest neurodegenerative disease of aging a...

What is the current status of trial NCT01609348?

This trial is currently completed. It is a NA study. The enrollment target is 5 participants. The study started on 2012-04. Estimated completion is 2017-01.

What conditions does trial NCT01609348 study?

This clinical trial studies the following conditions: Depression, Alzheimers Disease.

What interventions are being tested in trial NCT01609348?

The interventions under investigation include: Placebo (DRUG), Venlafaxine (DRUG).

Who is sponsoring clinical trial NCT01609348?

This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01609348 being conducted?

This trial has 2 study locations across Maryland, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Depression

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01609348's enrollment target sits among peer trials

5 674th of 679 higher than 5 of 679 other Depression trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT01609348, the US trial registry maintained by the National Library of Medicine. NCT01609348 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.